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Abstract
Background—Using a transcriptional profiling approach, we recently identified myeloid-related
protein-8/14 (MRP-8/14) to be expressed by platelets during acute MI. Elevated concentrations of
MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy
individuals, but have not been assessed with respect to prognosis in patients with ACS.
Methods—We performed a nested case-control study (n=237 case-control pairs) among patients
enrolled in the PROVE IT-TIMI 22 trial (mean follow-up 24 months) in order to investigate the risk
of cardiovascular death or myocardial infarction (MI) associated with MRP-8/14 measured at 30
days after an acute coronary syndrome (ACS).
Results—Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th,
75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5]
mg/L vs 4.0 [1.9, 10.1] mg/L, p = 0.020). The risk of a recurrent cardiovascular event increased with
each increasing quartile of MRP-8/14 (P-trend=0.007) such that patients with the highest levels had
a 2.0-fold increased odds (95% CI 1.1 – 3.6, p = 0.029) of a recurrent event after adjusting for standard
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risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of
MRP-8/14 and hsCRP showed significantly increased risk of cardiovascular death or MI compared
with patients with the lowest levels of both markers (adj OR 2.0; 95% CI 1.1 – 3.6).
Conclusions—MRP-8/14 may be a useful biomarker of platelet and inflammatory disease activity
in atherothrombosis and may serve as a novel target for therapeutic intervention.
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INTRODUCTION
In patients with acute coronary syndromes (ACS), recurrent cardiovascular events remain a
significant medical problem. Among patients managed with aggressive secondary preventive
interventions in the intensive statin therapy arm of the PROVE IT-TIMI 22 trial the rate of
death, myocardial infarction, unstable angina, need for revascularization or stroke was
approximately 22% over a 2-year period.1 Enhancements to our present tools for risk
stratification, especially those that may guide selection of optimal treatment regimens and/or
the development of new therapies, are of great interest.2 Novel biomarker development
strategies that originate from characterization of molecular and cellular changes during acute
atherothrombosis have particular potential to reveal new targets for both risk stratification and
therapy.3
Guided by the central role of the platelet in ACS, we previously profiled platelet messenger
RNA (mRNA) from patients with acute ST-segment myocardial infarction (MI) or stable
coronary artery disease.4 Since platelets lack a nucleus, the platelet mRNA, called the
transcriptome, provides a profile that generally reflects gene expression preceding a specific
biologic event (platelets circulate for 7–10 days), without the confounding possibility that the
acute event itself has provoked new gene transcription. Using this novel approach, we found
that one of the strongest discriminators of MI compared with stable disease was myeloid-related
protein-14 (MRP-14, also known as S100A9, calgranulin B).4 MRP-14 is a member of a family
of proteins that have intracellular and extracellular roles modulating calcium signaling,
arachadonic acid metabolism, cytoskeletal reorganization, and trafficking of neutrophils.5 In
humans, the most abundant form of MRP-14 is MRP-8/14, in which MRP-14 is bound to
MRP-8.6 Although MRP-8/14 is highly expressed in neutrophils, our recent data indicate that
platelets and megakaryocytes also contain MRP-14 mRNA and that platelets express
MRP-8/14 protein. We have recently validated the prognostic relevance of the MRP-14 gene
target with respect to the risk of first cardiovascular events (nonfatal myocardial infarction or
stroke, or cardiovascular death) among apparently healthy post-menopausal women followed
in the Women’s Health Study.4
The present study of patients with ACS enrolled in the PROVE-IT TIMI 22 Trial was designed
to test the hypothesis that elevated plasma levels of MRP-8/14 may identify patients with ACS
at heightened risk for recurrent cardiac events.
METHODS
Study Population
A nested case-control study was conducted among patients randomized in the PROVE-IT TIMI
22 trial. The design and results of PROVE-IT TIMI 22 have been reported previously.1 In
brief, PROVE-IT TIMI 22 was a multi-center, randomized, double-blind trial that evaluated
intensive (atorvastatin 80 mg daily) versus moderate (pravastatin 40 mg daily) stain therapy
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for the prevention of major adverse cardiac events in 4162 patients stabilized after ACS.
Randomization occurred in the first 10 days after presentation with MI or high risk unstable
angina (median 7 days). Patients were followed for 18 to 36 months after randomization (mean
24 months). Endpoints were adjudicated by an independent clinical events committee.
We designed a prospective, nested case-control study in which patients with CV death or MI
after 30 days (cases, n=237) were matched in a 1:1 ratio with patients who remained free of
recurrent cardiovascular events (controls, n=237). Cases and controls were matched on age
(within one year), sex, and smoking status (former smoker, current smoker, or nonsmoker).
Blood sampling
As part of the study protocol, a sample of venous blood was obtained in tubes containing EDTA
from the subjects at protocol-defined time-points. Plasma samples were stored at −80°C or
colder. Based upon results with our previous analysis of C-reactive protein, for this analysis,
we examined the concentration of MRP-8/14 at Day 30 follow-up after the residual
inflammatory influence of the qualifying ischemic event would have likely resolved. Case and
control specimens were assayed for high-sensitivity CRP and lipids, as previously described.
7 Plasma MRP-8/14 levels were measured by ELISA (Buhlmann Laboratories, Schonenbuch,
Switzerland). Performance characteristics of this assay include intra-assay imprecision of 4.8%
at 3.4 mg/L, inter-assay imprecision of 4.4% at 5.1 mg/L, minimal detectable concentration of
0.3 mg/L, and functional sensitivity (level of 15% imprecision) of 0.56 mg/L. When examined
in apparently healthy women, the median plasma concentration was 2.1 mg/L (25th, 75th
percentiles: 1.2, 3.4 mg/L).4 Data for the monocyte-derived marker neopterin were also
available in 76 patients. All biomarker testing was performed by personnel who were blinded
to treatment arms, outcomes, and results of other laboratory testing.
Statistical analysis
The plasma concentrations of MRP-8/14 are reported as the median (25th, 75th percentiles).
Baseline characteristics treated as continuous variables were compared with the Wilcoxon
signed rank test for paired data, and categorical variables were compared with McNemar’s test.
Given a non-parametric distribution of MRP-814, concentrations of the marker were compared
using the Wilcoxon signed rank test for paired data. Correlations between levels of MRP-8/14,
lipids, and CRP were examined with Spearman correlation coefficient. To evaluate its
association with CV death or MI, MRP-8/14 was analyzed categorized into quartiles according
to the concentration MRP-8/14 at 30 days. A landmark analysis was performed using
conditional logistic regression from the time of sampling (treating 30 days as time zero for the
analysis of subsequent events) and including all patients with an available MRP-8/14 result.
Confirmatory analyses excluding patients with non-fatal ischemic events prior to the 30 day
visit were also performed to eliminate possible confounding by recent cardiac events resulting
in an increase in MRP-8/14 at 30 days. Tests for linear trends were computed using an ordinal
variable for biomarker quartiles. Standard logistic regression was used for analyses within
unmatched subgroups. Adjusted risk estimates were obtained from regression models that, in
addition to accounting for matching (age, sex, smoking status), adjusted for the qualifying
syndrome (ST-elevation MI, non-ST elevation MI or unstable angina), history of diabetes,
history of HTN, prior coronary artery disease, prior peripheral arterial disease, prior
cerebrovascular disease, prior heart failure, aspirin at discharge, achieved LDL levels, other
biomarkers including hsCRP, and randomized treatment.
All analyses were performed using STATA v9.2 (STATA Corp., College Station, Texas). All
P-values were two-tailed, and values of less than 0.05 were considered to indicate statistical
significance. The authors had full access to the data and take responsibility for its integrity. All
authors have read and agree to the manuscript as written.
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RESULTS
We performed a nested case-control study (n=237 case-control pairs) among patients enrolled
in the PROVE IT-TIMI 22 trial to assess the risk of cardiovascular death or MI (mean follow-
up 24 months), associated with plasma levels of MRP-8/14 measured 30 days after ACS.
Patients with CV death or MI after 30 days (cases) were matched in a 1:1 ratio with patients
who remained free of recurrent cardiovascular events during study follow-up (controls). The
baseline characteristics of the 237 cases and 237 control subjects are shown in Table 1. As
anticipated, cases (including 41 cardiovascular deaths) had a higher frequency of
cardiovascular risk factors than controls. Because of matching, age, sex, and smoking status
were virtually identical between study groups. The observed range of MRP-8/14 in this study
was 0.3 to 101 mg/L with a median concentration of 4.9 mg/L. Women (p = 0.046), and patients
with a history of diabetes (p = 0.009) and hypertension (p = 0.006) were more likely to have
a concentration of MRP-8/14 above the median (Table 1b Online only). The concentration of
MRP-8/14 was not significantly associated with age, self-reported race, smoking status, or the
qualifying event (STEMI, NSTEMI, or UA), (p >0.05 for each). Spearman correlation
coefficients between MRP-8/14 and hsCRP, white blood cell count, neopterin (a monocyte-
derived marker), LDL, and HDL were 0.25, 0.14, 0.17, 0.045, and 0.060, respectively.
The concentration of MRP-8/14 at 30 days was significantly higher in patients with CV death
or new MI during subsequent follow-up (cases) than in patients who remained free of recurrent
events (controls) (Table 2, P=0.020). In matched-pair analysis accounting for age, sex and
smoking status, the relative odds of CV death or MI increased significantly with each increasing
quartile of baseline concentration of MRP-8/14 (Table 3, P-trend = 0.007) such that patients
in the highest versus lowest quartile had a 2-fold elevation in risk (OR 2.0; 95% CI 1.2 – 3.4;
P=0.009). The relative risk associated with MRP-8/14 for important subgroups, including those
allocated to intensive statin therapy, are shown in Figure 1. There was no significant
heterogeneity of the risk associated with MRP-8/14 among these subgroups.
After adjustment for unmatched clinical risk indicators (qualifying syndrome, history of
diabetes, history of hypertension, prior coronary artery, peripheral arterial or cerebrovascular
diseae, heart failure, aspirin at discharge, achieved LDL levels), and randomized treatment
allocation, the concentration of MRP-8/14 remained associated with the risk of CV death or
MI (Table 3, P-trend=0.017). When additionally adjusted for hs-CRP, patients in the highest
quartile of MRP-10 8/14 had a 2.0-fold higher odds of CV death or MI (95% CI, 1.1 – 3.6, p
= 0.029). This relationship persisted when patients with any non-fatal recurrent ischemic event
between enrollment and Day 30 were excluded (adjusted OR 2.0; 95% CI 1.1 – 3.8, p = 0.033).
The combined use of MRP-8/14 and hsCRP for risk stratification is illustrated in Figure 2,
showing an additive relationship with the risk of CV death or MI. When treated as a continuous
variable (log-transformed), each natural log increase in MRP-8/14 was associated with a 20%
increase in the risk of CV death or MI (p = 0.049), after adjusting for clinical risk indicators,
and biomarkers, including hsCRP. In an additional analysis limited to those case-control pairs
with measurement of lipoprotein phospholipase A2 activity (N=396), the risk associated with
the highest quartile of MRP-8/14 remained significant after adding this additional biomarker
to the model (adjusted OR 2.4; 95% CI 1.2 – 5.0, p = 0.014). Moreover, after further adjusting
for B-type natriuretic peptide (N=314), the risk associated with the highest quartile of
MRP-8/14 remained significant l (adjusted OR 2.5; 95% CI 1.1 – 5.7, p = 0.025).
The concentration of MRP-8/14 at 30 days were lower in patients treated with atorvastatin 80
mg daily compared with pravastatin 40 mg daily (4.0 mg/L vs. 5.6 mg/L, p = 0.046). There
was no detectable modification of the risk associated with MRP-8/14 based upon treatment
allocation (p-interaction = 0.84).
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DISCUSSION
This study demonstrates that in a cohort of patients with ACS, the plasma concentration of
MRP-8/14 is independently associated with the risk for recurrent cardiovascular events.
Notably, this protein expressed by both platelets and inflammatory cells was only weakly
correlated with hsCRP and monocyte-derived neopterin. Importantly, the association with
outcome was independent of traditional clinical risk indicators and hsCRP. These findings
provide valuable proof-in-principle for the platelet transcriptional profiling strategy leading to
the evaluation of MRP-8/14 in cardiovascular disease. The results also support the possible
relevance of platelets as participants in inflammatory processes underlying acute
atherothrombosis, and point toward a potential new therapeutic target.
MRP-8/14 as a Novel Biomarker
Platelets and neutrophils play important pathophysiologic roles in ACS,8, 9 and the
measurement of biomarkers related to their activity provides independent prognostic
information.10, 11 Like soluble CD40L,12 MRP-8/14 may reflect the interrelated activation
of platelets and inflammatory cells contributing to an environment that characterizes vulnerable
plaque and perhaps the “vulnerable” patient.13 Although plasma MRP-8/14 was previously
considered leukocyte-derived,6 our recent study raises the possibility that platelets and
megakaryocytes may serve as an additional source of MRP-8/14.4 Because of its ability to
regulate calcium signaling and promote cellular cytoskeletal reorganization,14 it is intriguing
to speculate that MRP-14 may be involved in the cellular events that also promote platelet-
mediated thrombosis. Nevertheless, additional experimental and clinical studies, including
interrogation of platelet mRNA in additional patient populations and evaluation of other soluble
biomarkers originating from neutrophils, are likely to be valuable in discerning the relative
contribution of platelets and inflammatory cells to the plasma concentration of MRP-8/14.
The serum concentration of MRP-8/14 is a useful biomarker of disease activity in inflammatory
disorders, such as rheumatoid arthritis and inflammatory bowel disease.15 Neutrophils and
monocytes highly express MRP-8/14.6 Inflammatory stimuli promote the surface expression
and secretion of MRP-8/14, where it functions, in part, as a chemoattractant regulating
leukocyte adhesion.16, 17 Patients with diabetes mellitus have elevated plasma levels of
MRP-8/14,18 and related members of the same family of proteins bind to receptor for advanced
glycation end-products (RAGE) and trigger pro-inflammatory and pro-thrombotic responses.
19 Thus, there are plausible potential pathophysiologic contributions from MRP-8/14
originating either from platelets or leukocytes.
Clinical and Scientific Implications
The present results have several implications. First, the findings support hypotheses linking
inflammation, platelet activation, and thrombosis in the pathogenesis of ACS.12 There is
growing evidence that neutrophils play an important pathophysiologic role in ACS.10, 20
MRP-8/14 is the most abundant cytosolic protein in neutrophils and is essential for the
recruitment of neutrophils during wound healing in vivo.14 Thus, it is possible that MRP-8/14
may not only be a marker of neutrophil activation, but also may be a direct contributor to
inflammatory and thrombotic responses during ACS. Indeed, observations in MRP-14-
deficient mice indicate that MRP-14 is essential for the recruitment of neutrophils at sites of
injury.14
Second, the data indicate that MRP-8/14 may add prognostic information to that conveyed by
standard risk factors and CRP in patients with recent ACS. This finding extends our observation
in otherwise healthy women at risk for first cardiovascular events among whom we observed
a 3.8-fold increase risk in any vascular event (P<0.001) among those with the highest levels
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of MRP-8/14. Additional investigation is needed to refine quantitative estimates of the risk
relationships with MRP-8/14 in this and other populations and to define its value as a potential
contributor to multi-marker strategies for risk assessment.2 It is noteworthy that consistent
with prior observations regarding potential pleiotropic effects of statins,21 that patients treated
with the intensive statin strategy tended toward lower levels of MRP-8/14 by 30 days. This
finding was of borderline statistical significance and warrants corroboration in additional
separate studies.
Third, these results provide an encouraging example of success in meeting the benchmark of
external clinical validation of a marker originating from a genomic-based strategy for novel
biomarker development.
Limitations
Several limitations of the study merit consideration. First, our study design does not permit us
to determine the precise cellular source of plasma MRP-8/14. The relative contributions of
platelets and leukocytes to the plasma pool of MRP-8/14 are the focus of ongoing studies.
Second, platelets possess a complex that processes pre-mRNA in the “mature” mRNA that is
translated into protein.22 Thus, it is possible that changes in mRNA processing may modulate
the platelet transcriptome (including mRNA for MRP-14) in response to activation during a
clinical event such as MI. Third, owing to the timing of blood sampling in this study, our results
can not be generalized to measurement of MRP-8/14 at the time of initial presentation. Fourth,
our case-control design does not permit us to fully evaluate the interaction of statin therapy
with the risk associated with the achieved levels of LDL cholesterol and MRP-8/14 during
statin therapy. Finally, data on recovery of MRP-8/14 after long-term storage are not available.
However, any variability introduced by loss of recovery would be expected to have drawn our
findings toward the null hypothesis.
Conclusion
In conclusion, we found that MRP-8/14 is independently associated with the risk of recurrent
cardiovascular events in patients with ACS. These data indicate that MRP-8/14 may be a useful
biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as
an interesting target to explore for therapeutic intervention.
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Figure 1.
Relative odds of CV death or MI associated with MRP-8/14 concentration above the median
stratified by sex, qualifying syndrome, and randomized treatment.
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Figure 2.
Adjusted relative odds of CV death or MI according to MRP-8/14 and hsCRP. Patients with
elevated MRP-8/14 and hsCRP were at 2.1 fold (95% CI 1.2 – 3.8) higher risk of CV death or
MI compared to those with a low plasma concentration of both biomarkers, after adjusting for
qualifying syndrome, history of diabetes, history of hypertension, prior MI, heart failure,
aspirin at discharge, achieved LDL levels, and randomized treatment allocation. There were
128, 108, 97 and 140 patients in the low MRP-8/14/low hsCRP, low MRP-8/14/high hsCRP,
high MRP-8/14/low hsCRP, and high MRP-8/14/high hsCRP groups respectively.
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Table 1
Characteristics of the Nested Case-Control Population
Controls
(n = 237)
Cases
(n = 237)
p value
Demographics
Age, yrs 61 (52, 70) 61 (52, 70) -
Female 52 (21.9%) 52 (21.9%) -
Risk Factors
Current smoker 95 (40.1) 95 (40.1) -
Hypertension 110 (46.4) 140 (59.1) 0.007
Diabetes 45 (19.0) 67 (28.3) 0.017
BMI (kg/m2) 28.1 (25.7, 30.6) 28.7 (25.8, 32.1) 0.06
Cardiovascular History
Coronary artery disease 96 (40.5) 125 (52.7) 0.008
Cerebrovascular disease 13 (5.5) 28 (11.8) 0.011
Peripheral arterial disease 15 (6.3) 40 (16.9) 0.0003
Presenting Characteristics
Qualifying event STEMI 64 (27.0) 83 (35.0) 0.060
NSTEMI 101 (42.6) 78 (32.9)
UA 72 (30.4) 76 (32.1)
Heart Failure 9 (3.8) 19 (8.1) 0.080
Concomitant therapies at discharge
Aspirin 192 (81.0) 170 (71.7) 0.021
Thienopyridine 142 (59.9) 145 (61.2) 0.84
Atorvastatin 80 mg 117 (49.4) 109 (46.0) 0.52
ACE inhibitors 117 (49.4) 131 (55.3) 0.22
Data are shown as N (%) for dichotomous variables and median (25th, 75th percentile) for continuous variables. STEMI = ST-elevation myocardial
infarction; NSTEMI = non-ST elevation myocardial infarction; UA = unstable angina; ACE = angiotensin converting enzyme
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Table 2
Biomarker Concentrations in Case and Controls
Controls Cases p value
MRP-8/18 (mg/L) 4.0 (1.9 – 10.2) 5.6 (2.8 – 13.5) 0.020
hs-CRP (g/L) 1.9 (0.8, 3.8) 2.5 (1.2, 5.8) 0.0006
Neopterin* 8.6 (7.4, 12.2) 8.9 (6.6, 11.7) 0.17
LpPLA2 activity 32.9 (25.9, 42.5) 36.5 (28.3, 47.5) 0.050
LDL-C (mg/dL) 74 (57, 98) 79 (57, 98) 0.17
HDL-C (mg/dL) 40 (33, 47) 41 (34, 48) 0.70
Triglycerides (mg/dL) 120 (85, 152) 123 (93, 186) 0.004
eGFR 76.8 (63, 90) 73.5 (63, 88) 0.16
Data are shown as median (25th, 75th percentile).
*
N = 76
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